TL;DR:
- H1 introduces GenosAI, a generative AI tool within Trial Landscape platform.
- GenosAI enhances clinical trial intelligence, enabling deep insights, efficiency, and cost reduction.
- Trial Landscape draws insights from vast healthcare data sources, including 490,000 trials and 240 million patients.
- GenosAI utilizes natural language processing for instant responses to complex queries.
- H1’s CEO sees GenosAI as a game-changer in the pharmaceutical industry.
- GenosAI is part of H1’s global data platform ensuring data privacy and reliability.
Main AI News:
In a significant stride towards enhancing clinical trial intelligence, H1 has introduced GenosAI, an innovative generative AI tool seamlessly integrated into their Trial Landscape platform. This cutting-edge addition is poised to revolutionize the way complex inquiries are analyzed and addressed within the healthcare industry.
Trial Landscape, a flagship offering from H1, empowers sponsors with the ability to pinpoint emerging sites of interest, centers of excellence, and investigators with diverse patient populations. Moreover, it facilitates the evaluation of site and Principal Investigator (PI) patient recruitment strategies while providing invaluable insights into the competitive landscape across various trials. With the introduction of GenosAI, clinical operations, feasibility, and medical teams can now harness the power of deep insights, expedite workflows, delve into new data paradigms, enhance operational efficiency, reduce costs, and accelerate their journey to market dominance.
What sets Trial Landscape apart is its capacity to draw insights from an extensive repository of data, encompassing more than 490,000 trials, 25 million publications, data on 10 million healthcare providers (including diversity-related data), records of 240 million patients, and a staggering 11 billion global claims. Furthermore, clients have the flexibility to seamlessly integrate their proprietary data, including historical trial performance metrics and feasibility questionnaire responses. GenosAI, equipped with the prowess of natural language processing (NLP), adeptly interprets and responds to advanced analytical queries, delivering a user experience akin to conversing with a ChatGPT-like AI. Users can effortlessly pose questions such as “Which sponsors are spearheading the most promising small cell prostate cancer trials?” or “What are the optimal sites for my phase 3 prostate cancer study?” and receive rapid responses, often within seconds.
Ariel Katz, CEO and co-founder of H1, expressed the potential of GenosAI, stating, “GenosAI has the potential to become a pharmaceutical company’s most impactful Large Language Model (LLM) tool. By amalgamating the capabilities of conversational AI with our unparalleled repository of healthcare data, we aim to grant sponsors access to the most comprehensive data and technology available. We anticipate that this will significantly influence the landscape of clinical trial diversity and efficacy.”
GenosAI is an integral component of H1’s global data platform, which harnesses a spectrum of technologies, ranging from machine learning (ML) to NLP, to establish a unified source of truth for healthcare data. The platform’s robust data privacy and security measures are bolstered by the utilization of Microsoft Azure’s Enterprise GPT-4. Additionally, the incorporation of Guardrails helps mitigate the common occurrence of healthcare language model hallucinations, while the Retrieval Augmented Generation (RAG) approach enriches the model with H1-specific data and knowledge.
Conclusion:
The introduction of GenosAI by H1 signifies a pivotal moment in the healthcare market. This innovative AI tool promises to redefine the landscape of clinical trials, offering pharmaceutical companies unparalleled access to data-driven insights and efficiency. As the industry embraces advanced AI solutions, the potential for improved clinical trial diversity and efficacy is substantial, promising a brighter and more patient-centric future for healthcare.
